Children who inherit genetic mutations from parents with early-onset Alzheimer’s typically show signs of dementia at the same ...
Researchers evaluated a neoantigen-targeting personalized cancer vaccine in patients with high-risk, fully resected clear ...
Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical ...
Learn more about whether Biogen Inc. or Neurocrine Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.
BOSTON - Allarity Therapeutics, Inc. (NASDAQ: ALLR), a micro-cap biopharmaceutical company valued at $4.79 million, has announced a new protocol for its ongoing clinical trial of stenoparib, a ...
Zacks.com on MSN17h
LLY's Q4 Earnings Beat, Mounjaro, Zepbound Sales Fall Shy of EstimatesEli Lilly and Company LLY reported fourth-quarter 2024 adjusted earnings per share (“EPS”) of $5.32, which beat the Zacks ...
Pharmaceutical Technology on MSN20h
Tripartite MoU signed for mRNA production platform in EgyptEVA Pharma of Africa, DNA Script and Quantoom Biosciences have signed a MoU to establish the mRNA production platform in Egypt.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback